Clinical trial
Novel Hormonal Therapies (NHTs) for the Treatment of Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Medicare Population
NCT06072196 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Novel Hormonal Therapies (NHTs) for the Treatment of Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Medicare Population
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 4, 2023
- Completion date
- December 18, 2024
- Enrollment
- 3,017 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.